Abologix obtains funding from the KICK FUND

ignaciofaus1
Dec 23, 2024
1 min read

Updated: Feb 28

Geneva, Switzerland, December 23, 2024 – Abologix has been awarded 100,000 CHF by the KICK FUND to progress its advanced preclinical development plan for monoclonal antibody H225 (a blocker of JAM-C, Junction Adhesion Molecule C).

Successful completion of the Innosuisse Innovation Project

Geneva, Switzerland, November 23, 2023 – Abologix successfully completes the Innosuisse-funded program for the initial characterization...

Nomination of product H225 as the lead preclinical candidate

Geneva, Switzerland, December 20, 2022 – Abologix nominates monoclonal antibody H225 (blocker of JAM-C, Junction Adhesion Molecule C) as...

Winners in Stage III of the Venture Kick competition

Geneva, Switzerland, May 26, 2021 – Abologix has been named one of the winners of the Venture Kick stage III start up competition. This...

Abologix obtains funding from the KICK FUND

Comentários

Back to Top